The test has a complicated name: The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. But the goal of the test, created by Fujirebio Diagnostics, is simple: Early detection of beta-amyloid plaques linked to the neurocognitive disease in adults 55 and older who are exhibiting signs and symptoms of the disorder.

The very first blood test for Alzheimer's disease detection has been green-lit by the US Food and Drug Administration (FDA), providing a simpler and less invasive method for early diagnosis and speedier intervention.

The Food and Drug Administration has cleared the blood test to help diagnose Alzheimer's disease, potentially making it easier to find and treat patients.